Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

98.93EUR
9:47am BST
Change (% chg)

€0.14 (+0.14%)
Prev Close
€98.79
Open
€98.80
Day's High
€99.09
Day's Low
€98.33
Volume
288,014
Avg. Vol
2,972,104
52-wk High
€123.90
52-wk Low
€88.81

Latest Key Developments (Source: Significant Developments)

Bayer Says Benefit/Risk Profile Of Essure Has Not Changed & Remains Positive
Monday, 9 Apr 2018 

April 9 (Reuters) - Bayer AG ::BAYER STATEMENT ABOUT ESSURE LABEL UPDATE.BAYER AG SAYS BENEFIT/RISK PROFILE OF ESSURE HAS NOT CHANGED AND REMAINS POSITIVE.  Full Article

U.S. FDA Says Issued Order To Restrict Sale & Distribution Of Bayer's Essure Device
Monday, 9 Apr 2018 

April 9 (Reuters) - U.S. Food And Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION SAYS ISSUED AN ORDER TO RESTRICT THE SALE AND DISTRIBUTION OF BAYER'S ESSURE DEVICE.NEW ESSURE LABELING RESTRICTS SALE TO HEALTH CARE PROVIDERS, FACILITIES THAT PROVIDE INFORMATION TO PATIENTS ABOUT RISKS, BENEFITS OF DEVICE.DETERMINED THAT SOME WOMEN STILL ARE NOT RECEIVING INFORMATION ABOUT THE KNOWN RISKS OF ESSURE BEFORE IMPLANTATION.  Full Article

Bayer Issues Voluntary Recall Of Alka-Seltzer Plus Products Due To Labelling Error ‍​
Thursday, 15 Mar 2018 

March 15 (Reuters) - Bayer Ag ::BAYER ISSUES VOLUNTARY RECALL OF ALKA-SELTZER PLUS PRODUCTS DUE TO LABELLING ERROR ‍​.BAYER AG - TO DATE, NO COMPLAINT HAS BEEN RECEIVED THAT RESULTED IN AN ADVERSE HEALTH CONSEQUENCE.BAYER AG - ‍​AFFECTED PACKAGES ARE BEING RECALLED BECAUSE THE INGREDIENTS ON THE FRONT STICKER MAY NOT MATCH ACTUAL PRODUCT IN CARTON.  Full Article

Monsanto Q1 Earnings Per Share $0.38
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Monsanto Co ::Q1 EARNINGS PER SHARE $0.38.Q1 EARNINGS PER SHARE VIEW $0.42 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE $0.41 FROM CONTINUING OPERATIONS.QTRLY TOTAL NET SALES $2,658 MILLION VERSUS $2,650 MILLION LAST YEAR.-CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018​.QTRLY TOTAL SEEDS AND GENOMICS SALES $1,770 MILLION VERSUS $1,848 MILLION LAST YEAR.INTACTA RR2 PRO(TM )SOYBEAN ADOPTION IN SOUTH AMERICA OFF TO A GOOD START IN Q1; ON PACE TO REACH 60 MILLION ACRES IN FY18.QUARTERLY RESULTS BENEFIT FROM HIGHER GLYPHOSATE PRICING.MONSANTO - EXPECTS GROWTH IN ITS PRETAX INCOME FOR FY 2018, BUT DID NOT PROVIDE SPECIFIC FINANCIAL GUIDANCE IN LIGHT OF PENDING COMBINATION WITH BAYER.MONSANTO - BRANDED ORDER MIX SUPPORTS EXPECTATIONS FOR 40 MILLION ACRES OF ROUNDUP READY 2 XTENDSOYBEANS IN FY 2018 IN U.S..MONSANTO SAYS CONTINUES PROGRESS TOWARDS CLOSURE OF MERGER WITH BAYER IN EARLY PART OF 2018.MONSANTO - ‍ EXPECTED GROWTH DRIVERS FOR 2018 ARE CONTINUED IMPROVEMENTS IN PRICING FOR GLYPHOSATE, ADOPTION OF NEW TECHNOLOGIES IN SEEDS AND GENOMICS.MONSANTO - CONTINUE TO EXPECT STRONG ADOPTION OF IMPROVED PRICING FOR GLYPHOSATE TO BE TEMPERED BY CHALLENGING GLOBAL CORN AND SOYBEAN PRICES.Q1 REVENUE VIEW $2.77 BILLION -- THOMSON REUTERS I/B/E/S.MONSANTO SEES ‍BENEFITS RELATED TO ASSET SALES,LICENSING CONTRIBUTIONS TO BE ABOUT 30 PERCENT BELOW ABOUT $350 MILLION PRE-TAX AVERAGE CONTRIBUTION FOR LAST 3 YRS.  Full Article

Bayer Announces Initiation Of Rolling Submission Of NDA In U.S. For Larotrectinib
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - BAYER AG ::INITIATION OF ROLLING SUBMISSION OF NDA IN U.S. FOR LAROTRECTINIB FOR TREATMENT OF TRK FUSION CANCERS​.‍COMPLETION OF NDA SUBMISSION EXPECTED IN EARLY 2018​.  Full Article

Bayer's Rivaroxaban Submitted To U.S. FDA For Approval
Monday, 11 Dec 2017 

Dec 11 (Reuters) - BAYER AG ::RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

Peptidream announces discovery collaboration agreement with Bayer
Monday, 20 Nov 2017 

Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.‍Entered into a multi-target discovery collaboration with Germany-based Bayer AG​.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion​.Also eligible to receive royalties on sales of any products that arise from collaboration​.  Full Article

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article

Bayer may terminate Loxo agreement if Larotrectinib is unapproved
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Loxo Oncology :Agreement with Bayer includes standstill provision preventing Bayer from acquiring 5 percent or more of co's voting securities​.Loxo says Bayer may terminate agreement if co gets CRL from U.S. Food and Drug agency with respect to Larotrectinib - SEC filing​.Bayer may terminate agreement if co does not get marketing approval for Larotrectinib by December 31, 2018​.  Full Article

Bayer AG News

EU mergers and takeovers (April 23)

BRUSSELS, April 23 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

» More BAYGn.DE News

Earnings vs. Estimates

» More Financials